Healthcare • Biotechnology
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Company profile from EODHD, stored Oct 29, 2026.
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 13, 2026 | — | — | — | -$2.1M | -$2.3M |
| Mar 2026filed May 18, 2026 | — | — | — | -$2.3M | -$2.3M |
| Dec 2025filed Mar 18, 2026 | — | — | — | -$613.2K | -$613.2K |
| Sep 2025filed Nov 12, 2025 | — | — | — | -$4.8M | -$4.8M |
| Jun 2025filed Aug 12, 2025 | — | — | — | -$5.5M | -$5.5M |
| Mar 2025filed May 14, 2025 | — | — | — | -$2.1M | -$2.1M |
| Dec 2024filed Dec 31, 2024 | — | — | — | -$1.1M | -$1.1M |
| Sep 2024filed Nov 14, 2024 | — | — | — | -$3.4M | -$3.4M |
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 18, 2026 | — | — | — | -$13.1M | -$13.1M |
| Dec 2024filed Dec 31, 2024 | — | — | — | -$8.8M | -$8.8M |
| Dec 2022filed Mar 14, 2023 | — | — | — | -$11.1M | -$11.1M |
| Dec 2021filed Jun 30, 2022 | — | — | — | -$1.7M | -$1.7M |
| Dec 2020filed Jun 30, 2021 | — | — | — | -$733.7K | -$733.7K |
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched ESLA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
599,647 shares short
+385,617 shares (+180.2%) vs Sep 30, 2026
1.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
214,030 shares short
+60,249 shares (+39.2%) vs Sep 15, 2026
1.5% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
153,781 shares short
+36,649 shares (+31.3%) vs Aug 31, 2026
1.1% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
117,132 shares short
+55,722 shares (+90.7%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
61,410 shares short
+13,356 shares (+27.8%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
48,054 shares short
-6,399 shares (-11.8%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
See the recorded cash amounts and dates behind ESLA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workSign in to see your position size
We’ll show you if ESLA is in your portfolio and how much it contributes.
Sign inLoading market dates
3 smart-money holders: institutions with a high Holder IQ
Sentiment: unknown
No recent insider trades detected.
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 4
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
15 filers reported a long position in ESLA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
99.9%
of the 4.8M shares 13-F filers reported
Moves vs Q1 2026
4 added4 trimmed
2 unchanged
Net shares held
-2.1%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | $4.1M · 4M shares | 4M | -3% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $433.5K · 416.9K shares | 416.9K | +9% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | $147K · 141.3K shares | 141.3K | -10.3% |
| 4 | VANGUARD FIDUCIARY TRUST CO | $67.5K · 64.9K shares | 64.9K | Unchanged |
| 5 | BlackRock, Inc. | $54.1K · 52K shares | 52K | +30.4% |
| 6 | STATE STREET CORP | $45K · 43.3K shares | 43.3K | Unchanged |
| 7 | RENAISSANCE TECHNOLOGIES LLC | $40.7K · 39.1K shares | 39.1K | -37.7% |
| 8 | NORTHERN TRUST CORP | $36.3K · 34.9K shares | 34.9K | +77.6% |
| 9 | US BANCORP \DE\ | $20.8K · 20K shares | 20K | +18.3% |
| 10 | Tower Research Capital LLC (TRC) | $3.4K · 3.3K shares | 3.3K | -31.9% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign inHolders of more than 5% of ESLA file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Aug 14, 2026 | ARMISTICE CAPITAL, LLC13G · passive · amended | 4.99%under 5% |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.